


Stopping life-threatening aneurysms.



Day
7

AAA **before** implantation



Day
7

Directly **after** implantation



Day
28

3 weeks later: Device stops AAA progression and even reduces size


Angiolutions' leadership team



PD Dr. med. Uwe Raaz
Co-Founder & Co-CEO



Dr. med. Isabel N. Schellinger
Co-Founder & Co-CEO



Marius Rummel
Chief Business Officer



Contacts

Angiolutions GmbH
Vahrenwalder Str. 269A
D-30179 Hannover

Tel. +49 15168189996
contact@angiolutions.com



www.angiolutions.com

MEDTECH



Company



Angiolutions revolutionizes the treatment of life-threatening abdominal aortic aneurysms (AAAs) with a unique solution that stops the disease in its tracks.

AAA is a dangerous disease of the biggest blood vessel of our body affecting 1 in 20 people. Although most AAAs are detected at an early stage, there presently is no treatment to stop the disease from progressing. If left untreated, AAAs often rupture fatally. Based on latest research findings, Angiolutions will offer the **world's first implant to stop AAA at an early stage**, offering renewed hope and improved outcomes to millions of AAA patients.

Products and technologies

Based on the founders' latest research findings discovered at Stanford University, Angiolutions is pioneering the development of a **first-of-its-kind minimally invasive class III implant to stop AAA at an early stage**. The device prevents further AAA progression and acts by reducing AAA biomechanical stress arising out of aortic pulse waves impacting the AAA.

Angiolutions' vision is to revolutionize AAA therapy and improve the lives of millions of patients around the world, allowing them to live longer and healthier lives.

Strengths

- First intervention to treat the root cause of the disease by eliminating the biomechanical stress (aortic pulse waves) that drives aneurysm progression – based on a radically new understanding of AAA growth mechanisms.
- Only device to stop progression of small AAA to large AAA
- Eliminates the need for complicated and risky prosthetic graft implantation and the risk for life-threatening complications
- Can be implanted by a wide range of physicians by standard catheter-based technique
- No general anesthesia
- No intensive care for patients and much shorter hospital stay in contrast to market standard
- Increases effectiveness and reduces costs for payers (-€21,914,33 /QALY)

Target clients

- Distributors for medical products (preferably with experience in cardiovascular devices)
- Hospitals treating abdominal aortic aneurysms
- Insurers
- Physicians specializing in the treatment of abdominal aortic aneurysms
- Regulatory experts in the field of cardiovascular medical devices
- Reimbursement specialists for class 3 implants (cardiovascular experience preferred)